Michael is President of Vectura Fertin Pharma. He has a wealth of pharma and consumer health knowledge and complementary expertise. He has significant experience in commercial strategy and a deep understanding of consumer, physician, payor and patient perspectives, as well as many disease areas and consumer health and device spaces. Previously, he was Chief Strategy Officer at Vectura Fertin Pharma. Before that, he held several positions of increasing responsibility at Philip Morris International, most recently as Senior Vice President, Commercialization, and was a Senior Partner at management consulting firm, Bain & Company. Michael holds an MBA from European Business School Universität in Germany.

Joel is Category Head NRT, looking to bring new, transformative innovation to the nicotine replacement therapy category. He has more than 20 years of experience in business development and commercial roles, the majority of which has been in pharma and healthcare. He previously held the position of President with Niconovum AB, a specialist NRT company. Prior to that, he was Global Marketing Director at GlaxoSmithKline, responsible for its global NRT portfolio. Joel holds an MBA from London Business School, and from his native U.S., both a master’s degree in public administration from New York University, and a bachelor’s degree in economics from Columbia University.

Antony is the Managing Director of Vectura. Acting as Vectura head, he is accountable for the P&L of Vectura and for commercial and operations activities. He has spent 25 years in senior executive roles in the healthcare sector and has been with Vectura since 2017. Prior to joining Vectura, he spent 19 years at Baxter International where he held global senior roles across Supply Chain and Manufacturing operations. Antony holds a master’s degree in Numerical Computation and a bachelor’s degree in Aeronautical Engineering from the University of Manchester, UK.

Michael is the Managing Director of Fertin Pharma. Before being appointed Managing Director Fertin, CDMO, Michael held the position as Chief Financial Officer at Fertin Pharma, a role he held since 2017. Michael brings with him a wealth of experience gained from other Chief Financial Officer roles in leading industries, such as food production equipment, renewable energy, and logistics. Prior to the executive roles, Michael held Financial Auditor roles with Arthur Andersen and Deloitte. He holds a master’s degree in business economics from Aarhus University, Denmark.

Sylvie is the Global Head People and Culture for Vectura Fertin Pharma and is based in Switzerland. She has held senior HR roles focusing on recruitment, organizational design, and change management at Michelin, Novartis, Genentech/Roche, McKesson, and Philip Morris International. She has lived and worked in Asia, America, and Europe and has a strategic knowledge of the entire pharmaceutical business value chain through her experience supporting research, development, manufacturing, and distribution. 

Sylvain has 20+ experience in the Finance sector and serves Vectura Fertin Pharma as Chief Financial Officer. He spent 14 years at Novartis, holding senior leadership roles in the pharmaceutical business, most recently as Chief Financial Officer Europe and Global Head Business Planning for Novartis Research, prior to joining Philip Morris International in December 2021. Sylvain started his career in 2002 as a financial auditor with Arthur Andersen and subsequently joined Ernst & Young and KPMG. Sylvain studied finance and economics, received his MBA from INSEAD, and is a certified public accountant.

Kim is the Chief Consumer Health Officer, responsible for building our branded consumer health business. Kim holds a PhD in biochemistry from Michigan State University and an MBA from London Business School. Before joining Vectura Fertin Pharma, he worked for over 15 years in the specialty ingredients B2B industry. Previously, he was a management consultant at Boston Consulting Group. 

With 35 years of experience in the Pharma, Biotech, Life Sciences and Diagnostics industries, Annika is well positioned to articulate the vision, define the strategy, build the capabilities, and develop the processes to ensure we guarantee our quality commitment to our external stakeholders and consumers, across our key product categories.

Begoña leads all of our BD&L efforts, including External Innovation, Search & Evaluation, Negotiations, Due Diligence and Alliance Management. Begoña joined from Novartis Pharma, where she held the role of Worldwide Head BD&L of the Opthalmology Franchise. Over the last 16 years she has built a proven track record in licensing deals and M&A. She holds a PhD in Drug Delivery from the London School of Pharmacy, a 3-year Postdoctoral Research fellowship at the Centre for Polymer Therapeutics (London School of Pharmacy) and a BSc in Biochemistry from Keele University. 

Lesley is responsible for the development and implementation of Vectura Fertin Pharma’s global communications strategy, managing programs to promote, enhance and protect the company’s reputation and ensure strong, positive engagement with employees and external stakeholders. She is based in the UK. She has over 20 years’ experience in leading and building communications functions across multiple industries and companies, including at Mundipharma, Syngenta GE Healthcare and AstraZeneca. Her earlier career saw her working in industries ranging from energy and technology to media and public healthcare. Lesley holds a Bachelor of Honors in Philosophy from the University of Birmingham, UK.

Klaus has over 19 years of experience within the healthcare industry, serving in various leadership roles across the pharma and medtech sectors. Klaus holds a Bachelors in Biophysics from the Niels Bohr Institute and a M.D. from the Panum Institute, both departments at the University of Copenhagen. He also holds a Graduate Diploma in Economics and Business Administration and an Executive MBA from Copenhagen Business School. In his role as Chief Medical Officer, Klaus will lead the creation and implementation of the development plan for the global programmes, and will define and execute Vectura Fertin Pharma’s clinical, medical, and regulatory strategies.

Julia is responsible for the creation of an end-to-end Cannabinoids category, as well as the network of external relationships, collaborations and partnerships that are required for success in this category. Before joining Vectura Fertin Pharma, Julia was at PMI R&D for 14 years, where she played a leading role in championing the science behind nicotine and smoke-free products, and in driving the tobacco harm reduction agenda. Julia holds a Ph.D. in Molecular Biology from the University of Cambridge, UK, and has an Executive MBA from the Business School Lausanne, Switzerland.

Geraldine is the Chief Scientific Officer of Vectura Fertin Pharma and responsible for scientific excellence and scientific governance. She chairs the Vectura Fertin Pharma development committee and acts as the liaison for Vectura Fertin Pharma’s Scientific Advisory Board. Previously Chief Scientific Officer and EVP Pharmaceutical Development at Vectura and Skyepharma, she also held scientific roles at Nektar, Vandsons, and Norton Healthcare, and has been associate professor of pharmacy at VCU. Geraldine is a pharmacist with a PhD in pharmaceutics from University of London. She has a 30-year career in inhaled product development.